An Article Sustaining The Relevance Of Theradiag's Work In Circulating microRNAs Published In Nature Reviews Clinical Oncology

Croissy-Beaubourg and Montpellier, March 11, 2014 - Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, is proud to announce that a scientific paper confirming the relevance of its research on circulating microRNAs in cancer has been published in Nature Reviews Clinical Oncolog[1], one of the review journals of Nature Publishing Group. Nature Reviews Clinical Oncology is the third most read journal in the field of oncology.

Heidi Schwarzenbach et al. in « Clinical relevance of circulating cell-free microRNAs in cancer [2] conducted a review of over a hundred articles on microRNAs published since 1993. According to their analysis « detection of levels of microRNAs in blood plasma and serum has the potential for earlier cancer diagnosis and to predict prognosis and response to therapy ». These findings apply to a variety of cancers (lung, breast, gynaecological, prostate, and gastrointestinal cancers). The authors also point out the importance of early diagnosis and monitoring of treatment as a key factor of efficient patient care.

"This review, in a journal of such scientific reputation, highlights the potential value of circulating microRNAs for the management of cancers that are complex to diagnose and to treat, and more generally to predict response to chemotherapy treatments. Theradiag is the only French company with a diagnostics and theranostics microRNA platform" comments Michel Finance, CEO of Theradiag.

Theradiag develops theranostics tests based on microRNAs for AIDS and cancer. In 2013, the company notably entered into a partnership agreement with the Cancer Institute of Montpellier to develop theranostics tools in rectal cancer.

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of "customized treatment", which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag market the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is also developing new diagnostics biomarkers thanks to its microRNA platform, in order to diagnose and monitor HIV/AIDS and rectal cancer. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 55 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

Theradiag
Relations investisseurs
Nathalie Trepo
Tél: 01 64 62 10 12
ntrepo@theradiag.com

NewCap.
Communication financière
et Relations Investisseurs
Valentine Brouchot /
Pierre Laurent
Tél. : 01 44 71 94 94
theradiag@newcap.fr

Alize RP
Relations Presse
Caroline Carmagnol
caroline@alizerp.com
Tél. : 06 64 18 99 59

Help employers find you! Check out all the jobs and post your resume.